REFERENCES
  1. Luoma JB, Chwyl C, Bathje GJ, et al. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. J Psychoactive Drugs 2020;52(4):289-299.
  2. Carhart-Harris R, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016;3:619-627.
  3. Carhart-Harris R, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 2018;235:399-508.
  4. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021;384(15):1402-1411.
  5. Sanches RF, de Lima Osorio F, dos Santos RG, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. J Clin Psychopharmacol 2016;36(1):77-81.
  6. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 2019;49(4):655-663.
  7. Carbonaro TM, Gatch MB. Neuropharmacology of N-N-dimethyltryptamine. Brain Res Bull 2016;126(Pt 1):74-88.
  8. Barker SA. N,N-dimethyltryptamine (DMT), an endogenous hallucinogen: past, present, and future research to determine its role and function. Front Neurol 2018;12:536.
  9. Riba J, McIlhenny EH, Bouso JC, Barker SA. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test Anal 2015;7(5):401-406.
  10. Ekman Schenberg E, Alexandre JFM, Filev R, et al. Acute biphasic effects of ayahuasca. PLOS One 2015;10(9):e0137202.
  11. Callaway JC, McKenna DJ, Grob CS, et al. Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol 1999;65(3):243-256.
  12. Yritia M, Riba J, Ortuno J, et al. Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of ayahuasca. J Chromatogr B Analyt Technol Biomed Life Sci 2002;779(2):271-281.
  13. Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 2003;306(1):73-83.
  14. Lanaro R, Mello SM, Francisco da Cunha K, et al. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in salva and serum after oral administration of ayahuasca in a religious context. Drug Test Anal 2021;13(3):664-678.
  15. Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 1994;51(2):85-97.
  16. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994;51(2):98-108.
  17. Gallimore AR, Strassman RJ. A model for the application of target-controlled intravenous infusion for a prolonged immersive DMT psychedelic experience. Front Pharmacol 2016;7:211.
  18. Strassman R. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 1996;73(1-2):121-124.
  19. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine: a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 2005;38(6):301-311.
  20. European Medicines Agency. Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07 Revision 1. 20 July 2017.
  21. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22(6):603-620.
  22. Timmermann C, Roseman L, Williams L, et al. DMT models the near-death experience. Front Psychol 2018;9:1424.
  23. Timmermann C, Roseman L, Schartner M, et al. Neural correlates of the DMT experiences assessed with EEG. Sci Rep 2019;9:16324.
  24. Allen GD. MODFIT: a pharmacokinetics computer program. Biopharm Drug Dispos 1990;11(6):477-498.
  25. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Inform J 1995;29(3):1039-1048.
  26. Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharmaceut Statist 2009;8(1):38-49.
  27. Kaplan J, Mandel LR, Stillman R, et al. Blood and urine levels of N-N-dimethyltryptamine following administration of psychoactive dosages to human subjects. Psychopharmacologia 1974;38(3):239-245.
  28. Eckernäs E, Bendrioua A, Cancellerini C, et al. Development and application of a highly sensitive LC-MS/MS method for simultaneous quantification of N,N-dimethyltryptamine and two of its metabolites in human plasma. J Pharm Biomed Anal 2022;212:114642.